Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Must Read: 3 Biotechs Rocking Today's Market

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

As the week comes to the close, we are reminded how that no matter how calm the broader market looks, there are always waves being made in the biotech sector. Today we have obesity drama, the death of a drug, and the lift of a clinical hold moving several high-profile stocks. Let's dive into these headlines and highlight key investor takeaways.

First up is Halozyme (Nasdaq: HALO  ) , our day's biggest gainer, soaring 30% on news that partner ViroPharma (Nasdaq: VPHM  ) can continue trials for Cinryze. The FDA put a hold on trials using Halozyme's subcutaneous platform in early August when HyQ was rejected. Shares were cut in half that day but rebounded nicely after a pipeline update for a phase 3 drug with Roche looked good. The lift of the clinical hold on Cinryze allays investor fears that Halozyme's platform was in jeopardy. With those fears abated, expect Halozyme to continue to trade back up to where it was before all of the drama began.

Astex Pharmaceuticals (Nasdaq: ASTX  ) investors unfortunately are on the other side of the drug development coin. The company announced it will discontinue development of amuvantinib after not meeting its primary endpoint in a phase 2 small-cell lung cancer trial. The good news is the drug appears safe, and if anyone is interested in licensing it out, Astex is all ears. Anyone? Hello?

Astex shares are off 9%, which isn't terrible considering the news. Amuvantinib was one of five phase 2 drug candidates, but since the drug isn't partnered, success would have been huge for the company. However, because Astex has so many partners, it is insulated from any single failure. Investors now are left to focus on Dacogen sales, which recently suffered a setback when the FDA denied an expanded indication into AML, and the rest of the company's development pipeline. Because of all the irons in the fire, this stock is definitely one to watch, but investors may be better served watching from a distance until we see further development of the pipeline.

Finally, that brings us to the hottest little corner of biotech: obesity drugs. VIVUS (Nasdaq: VVUS  ) is down 11% over worries that Qsymia will face rejection overseas. And this isn't just an idle rumor; it came straight from the horse's mouth -- a VIVUS press release! After discussion with the CHMP (the Euro-equivalent of our FDA) VIVUS "expects an opinion recommending against approval," but the company intends to either appeal or resubmit if the decision doesn't go their way. The big winner in this, of course, is rival Arena Pharmaceuticals (Nasdaq: ARNA  ) , up nearly 4% as any stumble by one leads to investor confidence in the other. Ultimately, both drugs should end up with EU approval, even if it takes a couple of tries, similar to what we saw here at home. Both stocks enjoyed massive gains over the past year, which should make investors leery, but if you believe in the long term future of obesity treatments, buying both stocks after 30% pullbacks from their 52-week highs will ensure you are poised to profit, no matter which company wears the sales crown.

But if you are looking to take sides, try The Motley Fool's new premium report on Arena Pharmaceuticals. This report outlines key opportunities and risks facing the company plus the must-watch areas for investors. Click here to receive your copy now!

Health care analyst David Williamson holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (2) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 21, 2012, at 2:11 PM, portefeuille wrote:

    CHMP (the Euro-equivalent of our FDA)


    not really. see

  • Report this Comment On September 21, 2012, at 2:21 PM, bhasa04 wrote:

    "Ultimately, both drugs should end up with EU approval, even if it takes a couple of tries, similar to what we saw here at home."

    Huh? What kind of logic is this? Phentermine is banned in Europe so VVUS will never be approved in Europe. In 2012 EU already rejected pediatric investigation application from VVUS while approving ARNA pediatric investigation application.

    Do some research before writing articles.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2026848, ~/Articles/ArticleHandler.aspx, 10/21/2016 9:50:29 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 34 minutes ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
ARNA $1.57 Down -0.02 -1.26%
Arena Pharmaceutic… CAPS Rating: **
ASTX.DL $0.00 Down +0.00 +0.00%
Astex Pharmaceutic… CAPS Rating: ***
HALO $9.40 Down -0.20 -2.08%
Halozyme Therapeut… CAPS Rating: ***
VPHM.DL $0.00 Down +0.00 +0.00%
ViroPharma CAPS Rating: ***
VVUS $1.10 Down -0.01 -0.90%
VIVUS CAPS Rating: **